跳至主要内容
临床试验/NCT00227461
NCT00227461Unknown1 期

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Kessler Foundation1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2005年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
50
试验地点
1
主要终点
Speech and language assessment

研究概览

简要总结

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

详细描述

In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Can give consent

排除标准

  • •Renal failure
  • •Pregnancy
  • •Other neurological condition

研究组 & 干预措施

Wait control

Other

Levitiracetam is started after a delay, with dosage and administration as described below.

干预措施: Levetiracetam first, then wait (Drug)

Treatment first

Experimental

Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.

干预措施: Wait first, then levetiracetam (Drug)

结局指标

主要结局

Speech and language assessment

时间窗: 6 months - 1year

次要结局

  • Memory assessment(6 months to 1 year)

研究者

发起方
Kessler Foundation
申办方类型
Other
责任方
Principal Investigator
主要研究者

A. M. Barrett, MD

Director, Stroke Rehabilitation Research

Kessler Foundation

研究点 (1)

Loading locations...

相似试验